U.S. FDA Grants Accelerated Approval to Bayer’s Hyrnuo (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
RegulatoryapprovedHyrnuoPositive
AI Analysis
Summary
Bayer's Hyrnuo (sevabertinib) received accelerated FDA approval as a first-line targeted therapy for HER2-mutated non-small cell lung cancer, following Priority Review and Breakthrough Therapy Designation.
Outcome Details
FDA grants accelerated approval following Priority Review and Breakthrough Therapy Designation
Importance:9/10
Sentiment:
0.95
FDA approvalaccelerated approvalbreakthrough therapypriority reviewHER2-mutated NSCLCtargeted therapy
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on September 9, 2026 8:09 PM